DOI: 10.1111/bjh.19014 ISSN:
Histiocytic neoplasms: Going, going, but not quite gone
Matthew Collin- Hematology
BRAF and MEK inhibitors have revolutionised the treatment of patients with high‐risk histiocytic neoplasms but does a complete response mean that treatment can be withdrawn?
Commentary on: Reiner et al. Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms. Br J Haematol 2023 (Online ahead of print). doi: